A primer on copay accumulators, copay maximizers, and alternative funding programs

Area of Science:

• Health economics
• Pharmaceutical access
• Patient affordability

Background:

• Insurers and employers utilize copay accumulator, copay maximizer, and alternative funding programs (AFPs) to mitigate spending on high-cost prescription drugs.
• These financial strategies aim to reduce the payer's liability for expensive medications.

Purpose of the Study:

• To elucidate the mechanisms of copay accumulator, copay maximizer, and AFPs.
• To enhance comprehension of these cost-shifting tactics.
• To guide clinicians and patients in managing medication access and affordability.

Main Methods:

• This primer provides a descriptive overview of the structural components of various insurance cost-containment programs.
• Analysis focuses on the impact of these programs on patient out-of-pocket expenses and medication access.

Main Results:

• Copay accumulators, maximizers, and AFPs decrease insurer spending but increase patient financial burden.
• These programs introduce significant complexities in accessing specialty medications.
• Patient affordability is negatively impacted, potentially leading to treatment gaps.

Conclusions:

• Understanding copay accumulator, copay maximizer, and AFP structures is crucial for stakeholders.
• Navigating these programs is essential to minimize treatment delays and non-initiation.
• These cost-shifting strategies necessitate informed approaches for effective medication access and affordability.